EUVIMEDEUVIMED entdecken
Open Access

Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531

Erin K Barr, Arlene Naranjo, Clare J Twist, Sheena C Tenney, Mary Lou Schmidt, Wendy B London iD, Julie Gastier-Foster, E Stanton Adkins, Peter Mattei, Michael H Handler, Katherine K Matthay iD, Julie R Park und 3 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Erin K Barr und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Texas Tech University Health Sciences, Lubbock, Texas, USA. Hauptthemen laut MEDLINE: Neuroblastoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: St. Baldrick's Foundation, NCI NIH HHS, NCTN Operations Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously reported excellent three‐year overall survival (OS) for patients with newly diagnosed intermediate‐risk neuroblastoma treated with a biology‐ and response‐based algorithm on the Children's Oncology Group study ANBL0531. We now present the long‐term follow‐up results.

Methods

All patients who met the age, stage, and tumor biology criteria for intermediate‐risk neuroblastoma were eligible. Treatment was based on prognostic biomarkers and overall response. Event‐free survival (EFS) and OS were estimated by the Kaplan‐Meier method.

Results

The 10‐year EFS and OS for the entire study cohort ( n = 404) were 82.0% (95% confidence interval (CI), 77.2%‐86.9%) and 94.7% (95% CI, 91.8%‐97.5%), respectively. International Neuroblastoma Staging System stage 4 patients ( n = 133) had inferior OS compared with non–stage 4 patients ( n = 271; 10‐year OS: 90.8% [95% CI, 84.5%‐97.0%] vs 96.6% [95% CI, 93.9%‐99.4%], p = .02). Infants with stage 4 tumors with ≥1 unfavorable biological feature ( n = 47) had inferior EFS compared with those with favorable biology ( n = 61; 10‐year EFS: 66.8% [95% CI, 50.4%‐83.3%] vs 86.9% [95% CI, 76.0%‐97.8%], p = .02); OS did not differ (10‐year OS: 84.4% [95% CI, 71.8%‐97.0%] vs 95.0% [95% CI, 87.7%‐100.0%], p = .08). Inferior EFS but not OS was observed among patients with tumors with ( n = 26) versus without ( n = 314) 11q loss of heterozygosity (10‐year EFS: 68.4% [95% CI, 44.5%‐92.2%] vs 83.9% [95% CI, 78.7%‐89.2%], p = .03; 10‐year OS: 88.0% [95% CI, 72.0%‐100.0%] vs 95.7% [95% CI, 92.8%‐98.6%], p = .09).

Conclusions

The ANBL0531 trial treatment algorithm resulted in excellent long‐term survival. More effective treatments are needed for subsets of patients with unfavorable biology tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaHumansMaleFemaleFollow-Up StudiesChild, PreschoolInfantChildSurvival RatePrognosisAdolescentAntineoplastic Combined Chemotherapy ProtocolsInfant, NewbornNeoplasm Staging

Stichwörter der Autor:innen

Intermediate risklong‐term follow‐upneuroblastomaoutcomes

Autor:innen und Institutionen

  • Department of Pediatrics, Texas Tech University Health Sciences, Lubbock, Texas, USA.
  • Department of Biostatistics, University of Florida Children's Oncology Group Statistics and Data Center, Gainesville, Florida, USA.
  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pediatrics and Pathology/Immunology, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Wendy B London, Katherine K Matthay, John M Maris, Susan L Cohn

Förderung

  • St. Baldrick's Foundation
  • NCI NIH HHS
  • NCTN Operations Center
  • National Cancer Institute

Zitieren

APA

Barr, E. K., Naranjo, A., Twist, C. J., Tenney, S. C., Schmidt, M. L., London, W. B., Gastier-Foster, J., Adkins, E. S., Mattei, P., Handler, M. H., Matthay, K. K., Park, J. R., Maris, J. M., Desai, A. V., & Cohn, S. L. (2024). Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31089

Vancouver

Barr EK, Naranjo A, Twist CJ, Tenney SC, Schmidt ML, London WB, et al. Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31089

BibTeX
@article{Barr2024,
  author = {Barr, Erin K and Naranjo, Arlene and Twist, Clare J and Tenney, Sheena C and Schmidt, Mary Lou and London, Wendy B and Gastier-Foster, Julie and Adkins, E Stanton and Mattei, Peter and Handler, Michael H and Matthay, Katherine K and Park, Julie R and Maris, John M and Desai, Ami V and Cohn, Susan L},
  title = {Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31089}
}
Kostenlos starten →